3 FDA Approvals In 2025 That Shift The Landscape For 2026

In this presentation, Precision’s Chief Medical Officer and former FDA Director, Division of Oncology 2, Harpreet Singh, MD breaks down 3 FDA approvals from last year that are impacting 2026. The approvals of Dordaviprone, Enhertu and Itvisma highlight shifting regulatory and development expectations. Learn what these landmark decisions mean for sponsors preparing for upcoming FDA submissions in oncology and rare diseases.